Promega Corporation is pleased to announce that The Scientist has named NanoLuc™ Luciferase Technology to its 2012 Top 10 Innovations. NanoLuc is a novel luciferase that is smaller, brighter, and more versatile than any current bioluminescent enzyme.
NanoLuc was first commercialized in May 2012 with 12 plasmid constructs and the Nano-Glo™ Reagent for reporter applications. NanoLuc is an enabling platform technology upon which Promega is developing additional assay solutions for difficult biology. The technology has already demonstrated its value to viral delivery and protein fusion applications. The versatility of NanoLuc is being further pursued by the Advanced Technologies Group and Research & Development teams at Promega.
In addition to in-house development, Promega is collaborating with complementary next-gen assay technologies to better serve basic and pharmaceutical research. Key collaborations using NanoLuc include coupling with 3D cell culture models (InSphero) and combining with genetically-defined reporter cell lines generated using the proprietary GENESIS™ gene editing technology (Horizon Discovery Ltd).
To learn more about this enabling technology, request a sample or view a webinar, please see www.promega.com/nanoluc.
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 2,500 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 15 countries and over 50 global distributors.